Jim Golden, Longmont’s longtime chief financial officer, recently retired after crunching numbers for the city for 45 years and four months — not that anyone’s counting. Originally hired in ...

The ice climbers and dry toolers are almost here. For Longmont Climbing Collective, the Ice Climbing and Dry Tooling World Cup is just around the corner. The competition, set for Feb. 22 and 23 ...

RIDE Longmont, the city’s new, on-demand public transportation service, has completed more than 10,000 rides since launching Dec. 9, according to data provided by the city. The service offers ...

Tonight, the Longmont City Council will select a replacement for Council member Marcia Martin, concluding the process initiated by her resignation after seven years of honorable service. While ...

Newly appointed Longmont city council member Matthew Popkin fields questions during a public interview on Jan. 21. Credit: Tyler Hickman After interviewing a field of 14 applicants, Longmont city ...

A Longmont Police Department officer is facing a federal civil rights lawsuit over allegations he falsified information in a financial crimes case, leading to a man’s arrest on suspicion of ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Three years after beginning construction in southwestern Wake County, the pharmaceutical company Amgen celebrated the completion of its $550 million manufacturing plant in the town of Holly ...

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

A substantial insider sell was reported on February 7, by Nancy A Grygiel, SVP & CCO at Amgen AMGN, based on the recent SEC filing. What Happened: Grygiel's recent move involves selling 1,589 ...